GenScript ProBio
Piscataway, NJ · Nanjing, CN
Program data pending ClinicalTrials.gov matching
· Last scored 2026-04-02
79.5
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (11)
✓ EMA GMP (9)
○ MHRA GMP
Quick Facts: GenScript ProBio
- Signal Score
- 79.5/100 (as of 2026-04-02)
- Quality Compliance
- 100.0/100 — No FDA inspection records found for this manufacturer
- Headquarters
- Piscataway, NJ · Nanjing, CN
- Modalities
- CAR-T, Cell Therapy
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
100.0
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Source: FDA Data Dashboard
No FDA inspection records found for this manufacturer · Quality score requires FDA inspection data
FDA InspectionsNo US records on file
EMA GMP Certificates9 on record
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
63.0
2 manufacturing sites
Sites: Piscataway, NJ, Nanjing, CN
Source: SEC EDGAR, press monitoring, company profiles
2 manufacturing sites
StatusConstrained
2 manufacturing sites
Sites: Piscataway, NJ, Nanjing, CN
Recent Press11 articles
2 manufacturing sites
EMA GMP Compliance 9 certificates
2025-11
2024-09
2024-09
2024-01
2023-12
2022-03
2020-01
2020-01
2019-07
Compliant
Non-Compliant
| Certificate | Site | Country | Inspection Date | Status |
|---|---|---|---|---|
| BE/GMP/2025/190 | ReprobiolAlternative Name:Reprobiol S.R.L. | Belgium | 2025-11-05 | COMPLIANT |
| IT-API/112/H/2025 | Probiotical S.p.A. | Italy | 2024-09-20 | COMPLIANT |
| IT/169/H/2025 | Probiotical S.p.A. | Italy | 2024-09-20 | COMPLIANT |
| ISF.405.32.2024.IP.1 WTC/0465_01_01/50 | Suprobion Sp. z o.o. sp.k. | Poland | 2024-01-24 | COMPLIANT |
| BE/GMP/2023/133 | Reprobiol | Belgium | 2023-12-20 | COMPLIANT |
| DK H 10000541 | Deerland Probiotics & Enzymes A/S | Denmark | 2022-03-31 | COMPLIANT |
| DK IMP 00133120 | Deerland Probiotics & Enzymes A/S | Denmark | 2020-01-23 | COMPLIANT |
| DK H 00133120 | Deerland Probiotics & Enzymes A/S | Denmark | 2020-01-23 | COMPLIANT |
| IT-API/9/H/2020 | PROBIOTICAL S.P.A. | Italy | 2019-07-19 | COMPLIANT |
Source: EMA EudraGMDP · Retrieved Apr 05, 2026
Recent News 11 articles
GenScript reports strong fiscal 2025 results from platform strategy - Vietnam Investment Review - VIR
GenScript reports strong fiscal 2025 results from platform strategy Vietnam Investment Review - VIR
GenScript launches first European mRNA production hub in Delft, bolstering EU biotech leadership - Indian Pharma Post
GenScript launches first European mRNA production hub in Delft, bolstering EU biotech leadership Indian Pharma Post
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth - Bolsamania
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth Bolsamania
GenScript launches first European mRNA production hub in Delft, bolstering EU biotech leadership - Indian Pharma Post
GenScript launches first European mRNA production hub in Delft, bolstering EU biotech leadership Indian Pharma Post
GenScript launches first European mRNA production hub in Delft, bolstering EU biotech leadership - Indian Pharma Post
GenScript launches first European mRNA production hub in Delft, bolstering EU biotech leadership Indian Pharma Post
GenScript opens its first European mRNA production site - Scientist Live
GenScript opens its first European mRNA production site Scientist Live
GenScript opens its first European mRNA production site - Scientist Live
GenScript opens its first European mRNA production site Scientist Live
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub - BioSpace
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub BioSpace
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub - The AI Journal
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub The AI Journal
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub - BeBeez International
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub BeBeez International
GenScript Opens First European mRNA Production Facility In Delft Strengthening Global Biotechnology Platform - BioPharma APAC
GenScript Opens First European mRNA Production Facility In Delft Strengthening Global Biotechnology Platform BioPharma APAC
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 92.2
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 90.7
CAR-T, Cell Therapy
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.5
CAR-T, Cell Therapy
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 82.9
CAR-T, Cell Therapy, AAV
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 80.2
CAR-T, Cell Therapy, AAV, Lentiviral